Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Therapeutics Goods Administration ×

Therapeutics Goods Administration

This funder is selected. Its supporting articles are shown below.

Therapeutics Goods Administration1

Articles mentioning Therapeutics Goods Administration

1 articles · page 1 of 1

Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial

bmjno · abstract · 2025-12-23 · 1 matching annotations

92.6%

Therapeutics Goods Administration spironolactone famciclovir MS Australian and New Zealand Clinical Trial Registry progressive multiple sclerosis

…istration number The STOP-MS trial has been acknowledged by the Therapeutics Goods Administration under the Clinical Trial Notification scheme (CT-2023-CTN-03 50…

Browse funders

Therapeutics Goods Administration

Articles mentioning Therapeutics Goods Administration

Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial